| Literature DB >> 35307285 |
Nicole M Grogan Fleege1, Erin F Cobain2.
Abstract
Breast cancer is the most commonly diagnosed cancer and is the leading cause of cancer death in women worldwide. Several factors increase the risk of breast cancer development, including patient characteristics, lifestyle habits, and predisposing genetic mutations. Once a diagnosis of breast cancer has been established, treatment decisions are guided by breast cancer stage and phenotype. Immunohistochemistry is used to quantify estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2) expressions. In this chapter, we will focus on the management of localized and metastatic breast cancer, guided by the breast cancer hormone receptor status (ER and PR expression) and HER2 expression identified at diagnosis.Entities:
Keywords: Breast cancer; Chemotherapy; Endocrine therapy; Estrogen receptor; Human epidermal growth factor 2
Mesh:
Substances:
Year: 2022 PMID: 35307285 DOI: 10.1016/j.bpobgyn.2022.02.004
Source DB: PubMed Journal: Best Pract Res Clin Obstet Gynaecol ISSN: 1521-6934 Impact factor: 5.237